vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted) (2020 - 2026)
vTv Therapeutics' (VTVT) quarterly EPS (Weighted Average and Diluted) came in at $1.65 in Q1 2026, up 314.29% year-on-year from $0.4 in Q1 2025, and up 512.5% quarter-over-quarter from -$0.4 in Q4 2025.
vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
vTv Therapeutics has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting $1.65 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $1.65, up 314.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.75 (up 74.66% YoY), and the FY2025 annual result was -$3.2, changed 0.0% from the prior year.
- EPS (Weighted Average and Diluted) came in at $1.65 for Q1 2026 at vTv Therapeutics, up from -$0.4 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.65 in Q1 2026 to a low of -$9.78 in Q4 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.88 (2024), against an average of -$1.44.
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 6625.0% in 2023 and surged 314.29% in 2026, its largest moves.
- vTv Therapeutics' EPS (Weighted Average and Diluted) stood at -$9.78 in 2022, then surged by 82.92% to -$1.67 in 2023, then surged by 70.06% to -$0.5 in 2024, then increased by 20.0% to -$0.4 in 2025, then jumped by 512.5% to $1.65 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $1.65 (Q1 2026), -$0.4 (Q4 2025), and -$1.08 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | vTv Therapeutics | 426.76 Mn | 426.76 Mn | - | 1.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.65 |
| Dec 31, 2025 | -0.40 |
| Sep 30, 2025 | -1.08 |
| Jun 30, 2025 | -0.92 |
| Mar 31, 2025 | -0.77 |
| Dec 31, 2024 | -0.50 |
| Sep 30, 2024 | -0.88 |
| Jun 30, 2024 | -0.81 |
| Mar 31, 2024 | -1.17 |
| Dec 31, 2023 | -1.67 |
| Sep 30, 2023 | -3.19 |
| Jun 30, 2023 | -2.69 |
| Mar 31, 2023 | -2.16 |
| Dec 31, 2022 | -9.78 |
| Sep 30, 2022 | -0.05 |
| Jun 30, 2022 | -0.04 |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -8.19 |
| Sep 30, 2021 | -0.02 |
| Jun 30, 2021 | -0.01 |